Chengdu Zenitar Biomedical Technology Co., Ltd.

9th Floor, Building E3, Biomedical Incubation Park, Xinchuan Road, High-tech Zone, Chengdu, 四川省, China

Clinical Trials

7 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

56.5%

Phase 2

30.4%

Phase 3

8.7%

Not Applicable

4.3%

Trial Status Distribution

Active, not recruiting

13.0%

Completed

30.4%

Not yet recruiting

17.4%

Recruiting

34.8%

Terminated

4.3%

Clinical Trials

Trials sponsored by this organization (23)

Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

Phase 2

Not yet recruiting

interventional

Nov 2026105 participants

Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets

Phase 1

Not yet recruiting

interventional

Oct 202640 participants

Mass Balance Study of [¹⁴C]Purinostat Mesylate for Injection in Healthy Participants

Phase 1

Not yet recruiting

interventional

Sep 20266 participants

A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis

Phase 2

Recruiting

interventional

Mar 202664 participants

A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

Phase 3

Recruiting

interventional

Feb 2026105 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

Back to Organizations

Chengdu Zenitar Biomedical Technology Co., Ltd.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (23)

Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets

Mass Balance Study of [¹⁴C]Purinostat Mesylate for Injection in Healthy Participants

Phase I Clinical Study of ZL-65 Tablet in Healthy Adult Participants in China

Mass Balance Study of [14C] Flonoltinib Maleate

A Clinical Study of ZL-85FA Tablets

A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis

A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

Approvals

News